Posted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma because Oncopeptides did not provide an evidence submission.
NICE will review this decision if Oncopeptides decides to make a submission.
